Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

11 Nov 2021

Abstract excerpt

In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort study, cases with a germline BRCA1/2 mutation (gBRCA; n = 75) were matched 1:2 with non-gBRCA controls (n = 150) by treatment arm, lymph node status, and age to evaluate pCR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Cancer Genomics and Diagnostics
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34764307
DOI: 10.1038/s41523-021-00349-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightnessPMID 34764307Read ↗

Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple Negative Breast CancerSemantic proximity Read ↗

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trialSemantic proximity Read ↗

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).Semantic proximity Read ↗

Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast CancerSemantic proximity Read ↗

Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trialSemantic proximity Read ↗

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab.Semantic proximity Read ↗

BRCA1/2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisSemantic proximity Read ↗

Research advances and new challenges in overcoming triple-negative breast cancerSemantic proximity Read ↗

Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.Semantic proximity Read ↗

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.Semantic proximity Read ↗

Association of tumor immune infiltration and prognosis with homologous recombination repair genes mutations in early triple-negative breast cancer.Semantic proximity Read ↗

TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.